How Investors May Respond To Zoetis (ZTS) Pivot Toward High-Value Pet Treatments Amid Fewer Vet Visits

• On March 17, 2026, Zoetis CEO and Director Kristin C. Peck presented at the virtual KeyBanc Capital Markets Healthcare Forum, outlining the company’s latest views on the animal health market.
• The discussion came as data show pet owners are cutting back on routine vet visits but still paying for higher-value treatments, diagnostics, and medicines when animals become seriously ill, reshaping how companies like Zoetis generate revenue.
• Now we’ll explore how resilient spending on high-value pet treatments, despite fewer clinic visits, may influence Zoetis’ existing investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Zoetis Investment Narrative Recap

To own Zoetis, you have to believe pet owners will keep prioritizing effective treatments and medicines even as they cut back on routine vet visits. The recent KeyBanc forum mainly reinforces that view rather than changing it, with the key short term catalyst still centered on execution in companion animal therapeutics and the biggest risk remaining competitive and adoption pressures across core franchises like dermatology and osteoarthritis pain.

The February 2026 guidance for full year revenue of US$9.825 billion to US$10.025 billion and diluted EPS of US$6.65 to US$6.75 is the announcement that most directly frames this discussion. It gives a reference point for how much resilience in high value treatments is already embedded in expectations, while leaving open how trends in vet visit patterns and Librela adoption could tilt results within or outside that range.

Yet beneath this steady picture, one emerging risk around competitive pressure and pricing power is something investors should be aware of...

Read the full narrative on Zoetis (it's free!)

Zoetis' narrative projects $10.9 billion revenue and $3.2 billion earnings by 2028. This requires 5.2% yearly revenue growth and about a $0.6 billion earnings increase from $2.6 billion.

Uncover how Zoetis' forecasts yield a $151.00 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Zoetis could reach about US$11.6 billion of revenue and US$3.4 billion of earnings by 2029, so you should weigh how persistent vet visit declines and shifting buyer power might challenge or support that stronger growth story as you compare different viewpoints.

Explore 9 other fair value estimates on Zoetis - why the stock might be worth as much as 82% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Zoetis research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zoetis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zoetis' overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com